Early buyers will receive 25% discount on the report

 Global Contrast Media Market – Forecasts Till 2018

Published on January 31, 2015
Report Code: 120
  • The global market is broadly segmented into barium-based, iodinated and gadolinium-based contrast media. These products are further categorized based on the medical procedure (X-ray, CT, MRI, ultrasound, and catheterization laboratory), route of administration (oral, injection, rectal, and urethral), medical indication (cardiovascular, respiratory, musculoskeletal, gastrointestinal, and neurology, nephrology and oncology) and finally application (radiology, interventional radiology and interventional cardiology). The global market is worth $6.2 billion in 2012, and estimated to grow at a CAGR of 6.8% to reach $8.6 billion by 2017.

    Iodinated contrast media will drive the overall growth of the market due to its applicability in various modalities like X-ray, CT, MRI scans, ultrasound and cath lab procedures. A fall is expected in the growth rate of barium-based products since certain toxicity issues of chemical peritonitis have been reported, leading to their discontinuation by major players. Iodinated contrast agent have widespread applications in medical imaging and hence, iodinated contrast media contribute the highest to this industry. This segment is expected to grow at the highest pace compared to other segments (barium-based and gadolinium-based), mainly due to its proven efficacy in diagnostic imaging and reduced toxicity issues. North America comprises of the largest market that uses these media in radiological examinations, followed by Europe. This is attributed to the fact that major players are located in these regions with easy access and extensive use of contrast agentin almost all radiological examinations.

    Contrast media have been in use in medical diagnostic procedures since mid 1950s and is a fairly mature market in 2012. Yet, it shows good potential to grow in the next five years due to technological advances in medical imaging like low-cost CT imaging and functional MRI. The ever-increasing cancer and cardiac mortality rates globally, growth of medical imaging in emerging markets, coupled with an increase in the demand for diagnostic image-guided procedures are foreseen to act as drivers for the growth of this market. However, some of the major economies in the world are undergoing healthcare reforms which bring certain restraints in terms of reimbursement of contrast agent. Also, the economic slowdown of 2008 has proved to be another decelerating factor hindering the growth of this market.


  • 1 INTRODUCTION
      1.1 KEY TAKE-AWAYS
    1.2 REPORT DESCRIPTION
    1.3 MARKETS COVERED
    1.4 STAKEHOLDERS
    1.5 RESEARCH METHODOLOGY
    1.5.1 MARKET SIZE
    1.5.2 MARKET SHARE
    1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES
    1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES

    2 EXECUTIVE SUMMARY

    3 MARKET OVERVIEW
      3.1 INTRODUCTION
    3.2 MARKET SEGMENTATION
    3.3 MARKET DYNAMICS
    3.3.1 DRIVERS
    3.3.1.1 INCREASING DEMAND FOR DIAGNOSTIC & IMAGE GUIDED PROCEDURES INFLUENCES CONTRAST MEDIA SALES
    3.3.1.2 TECHNOLOGICAL ADVANCEMENTS TO SPUR THE CONTRAST MEDIA MARKET
    3.3.1.3 INCREASING INCIDENCE & MORTALITY OF CANCER & CARDIAC DISEASES TO BOOST GROWTH OF CONTRAST MEDIA
    3.3.1.4 GROWTH OF MEDICAL IMAGING TECHNOLOGY IN EMERGING MARKETS
    3.3.2 RESTRAINTS
    3.3.2.1 MAJOR ECONOMIES UNDERGOING HEALTHCARE REFORMS TO AFFECT THE SALES ON CONTRAST MEDIA
    3.3.2.2 ECONOMIC SLOWDOWN TO INHIBIT GROWTH
    3.3.3 OPPORTUNITIES
    3.3.3.1 GROWING INVESTMENT POTENTIAL IN IMMATURE EMERGING MARKETS
    3.3.3.2 ADVENT OF NOVEL CONTRAST AGENTS COMBINING PROPERTIES OF CONTRAST MEDIA & RADIOPHARMACEUTICALS
    3.3.4 BURNING ISSUE – TOXICITY
    3.3.4.1 NEPHROGENIC SYSTEMIC FIBROSIS (NSF)
    3.3.4.2 CONTRAST-INDUCED NEPHROTOXICITY (CIN)
    3.3.5 TECHNOLOGY TRENDS
    3.3.5.1 N1177 – A REVOLUTIONARY MACROPHAGE LABELING AGENT
    3.3.5.2 SPAGO PIX – ACCURATE VISUALIZATION OF TUMORS WITH MRI
    3.3.5.3 CMC-001 – FOCUSED ON LIVER MRI
    3.4 MARKET SHARE ANALYSIS

    4 BY PRODUCT
      4.1 INTRODUCTION
    4.2 BARIUM-BASED CONTRAST MEDIA
    4.2.1 TECHNICAL OVERVIEW
    4.2.2 MARKET DYNAMICS
    4.2.3 MARKET ANALYSIS
    4.3 IODINATED CONTRAST MEDIA
    4.3.1 TECHNICAL OVERVIEW
    4.3.2 MARKET DYNAMICS
    4.3.3 MARKET ANALYSIS
    4.3.4 TYPES – LOW-OSMOLAR AND HIGH-OSMOLAR
    4.3.4.1 LOW-OSMOLAR CONTRAST MEDIA (LOCM)
    4.3.4.1.1 TECHNICAL OVERVIEW
    4.3.4.1.2 MARKET ANALYSIS
    4.3.4.2 HIGH-OSMOLAR CONTRAST MEDIA (HOCM)
    4.3.4.2.1 TECHNICAL OVERVIEW
    4.3.4.2.2 MARKET ANALYSIS
    4.4 GADOLINIUM-BASED CONTRAST MEDIA
    4.4.1 TECHNICAL OVERVIEW
    4.4.2 MARKET DYNAMICS
    4.4.3 MARKET ANALYSIS

    5 BY ROUTE OF ADMINISTRATION
      5.1 INTRODUCTION
    5.2 ORAL CONTRAST MEDIA
    5.2.1 TECHNICAL OVERVIEW
    5.2.2 MARKET DYNAMICS
    5.2.3 MARKET ANALYSIS
    5.3 INJECTABLE CONTRAST MEDIA
    5.3.1 TECHNICAL OVERVIEW
    5.3.2 MARKET DYNAMICS
    5.3.3 MARKET ANALYSIS
    5.3.4 INJECTABLE CONTRAST MEDIA – TYPES
    5.3.4.1 INTRAVENOUS (IV)
    5.3.4.2 INTRA-ARTERIAL (IA)
    5.4 RECTAL CONTRAST MEDIA
    5.4.1 TECHNICAL OVERVIEW
    5.4.2 MARKET DYNAMICS
    5.4.3 MARKET ANALYSIS
    5.5 URETHRAL CONTRAST MEDIA
    5.5.1 TECHNICAL OVERVIEW
    5.5.2 MARKET DYNAMICS
    5.5.3 MARKET ANALYSIS

    6 BY MEDICAL PROCEDURE
      6.1 INTRODUCTION
    6.2 X-RAY
    6.2.1 TECHNICAL OVERVIEW
    6.2.2 MARKET DYNAMICS
    6.2.3 MARKET ANALYSIS
    6.3 COMPUTED TOMOGRAPHY (CT)
    6.3.1 TECHNICAL OVERVIEW
    6.3.2 MARKET DYNAMICS
    6.3.3 MARKET ANALYSIS
    6.4 MAGNETIC RESONANCE IMAGING (MRI)
    6.4.1 TECHNICAL OVERVIEW
    6.4.2 MARKET DYNAMICS
    6.4.3 MARKET ANALYSIS
    6.5 ULTRASOUND
    6.5.1 TECHNICAL OVERVIEW
    6.5.2 MARKET DYNAMICS
    6.5.3 MARKET ANALYSIS
    6.6 CATHETERIZATION LABORATORY (CATH LAB)
    6.6.1 TECHNICAL OVERVIEW
    6.6.2 MARKET DYNAMICS
    6.6.3 MARKET ANALYSIS

    7 BY INDICATION
      7.1 INTRODUCTION
    7.2 CARDIOVASCULAR DISORDERS
    7.2.1 MARKET DYNAMICS
    7.2.2 MARKET ANALYSIS
    7.3 NEUROLOGICAL DISORDERS
    7.3.1 MARKET DYNAMICS
    7.3.2 MARKET ANALYSIS
    7.4 RESPIRATORY DISEASES
    7.4.1 MARKET DYNAMICS
    7.4.2 MARKET ANALYSIS
    7.5 GASTROINTESTINAL DISORDERS
    7.5.1 MARKET DYNAMICS
    7.5.2 MARKET ANALYSIS
    7.6 ONCOLOGY
    7.6.1 MARKET DYNAMICS
    7.6.2 MARKET ANALYSIS
    7.7 MUSCULOSKELETAL ANOMALIES
    7.7.1 MARKET DYNAMICS
    7.7.2 MARKET ANALYSIS
    7.8 NEPHROLOGICAL DISORDERS
    7.8.1 MARKET DYNAMICS
    7.8.2 MARKET ANALYSIS

    8 BY APPLICATION
      8.1 INTRODUCTION
    8.2 RADIOLOGY
    8.2.1 TECHNICAL OVERVIEW
    8.2.2 MARKET DYNAMICS
    8.2.3 MARKET ANALYSIS
    8.3 INTERVENTIONAL RADIOLOGY
    8.3.1 TECHNICAL OVERVIEW
    8.3.2 MARKET DYNAMICS
    8.3.3 MARKET ANALYSIS
    8.4 INTERVENTIONAL CARDIOLOGY
    8.4.1 TECHNICAL OVERVIEW
    8.4.2 MARKET DYNAMICS
    8.4.3 MARKET ANALYSIS

    9 GEOGRAPHIC ANALYSIS
      9.1 INTRODUCTION
    9.2 NORTH AMERICA
    9.3 EUROPE
    9.4 ASIA-PACIFIC
    9.5 REST OF THE WORLD (ROW)

    10 COMPETITIVE LANDSCAPE
       10.1 INTRODUCTION
    10.2 MERGERS & ACQUISITIONS
    10.3 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES
    10.4 NEW PRODUCT LAUNCH
    10.5 EXPANSION
    10.6 APPROVALS
    10.7 OTHER DEVELOPMENTS

    11 COMPANY PROFILES
       (OVERVIEW, FINANCIALS, PRODUCTS & SERVICES, STRATEGY, AND DEVELOPMENTS)* Ø SNAPSHOT
    11.1 AMAG PHARMACEUTICALS, INC.
    11.2 BAYER HEALTHCARE PHARMACEUTICALS
    11.3 BRACCO IMAGING SPA (A SUBSIDIARY OF BRACCO S.P.A)
    11.4 COVIDIEN
    11.5 CMC CONTRAST AB
    11.6 DAIICHI SANKYO CO., LTD.
    11.7 GE HEALTHCARE
    11.8 GENOVIS AB
    11.9 GUERBET GROUP
    11.10 LANTHEUS MEDICAL IMAGING, INC.
    11.11 NANOPET PHARMA GMBH
    11.12 NANOSCAN IMAGING, LLC
    11.13 SANOCHEMIA PHARMAZEUTIKA AG
    11.14 SPAGO IMAGING AB (A SUBSIDIARY OF ACCELERATOR NORDIC AB)
    11.15 SUBHRA PHARMA PRIVATE, LTD
    11.16 TAEJOON PHARM CO., LTD.
    11.17 TARGESON, INC.
    11.18 UNIJULES LIFE SCIENCES, LTD.
    *DETAILS ON FINANCIALS, PRODUCT & SERVICES, STRATEGY, AND DEVELOPMENTS MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.
    LIST OF TABLES

    TABLE 1 GLOBAL CONTRAST MEDIA MARKET, BY PRODUCT,2010 – 2017 ($MILLION)
    TABLE 2 BY GEOGRAPHY, 2010 – 2017 ($MILLION)
    TABLE 3 CLASSIFICATION OF GBCAS BY U.S. FDA BASED ON NUMBER OF NSF CASES
    TABLE 4 MARKET REVENUE, BY PRODUCT,2010 – 2017 ($MILLION)
    TABLE 5 MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
    TABLE 6 BARIUM-BASED CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY, 2010-2017 ($MILLION)
    TABLE 7 IODINATED CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
    TABLE 8 IODINATED MARKET REVENUE, BY TYPE,2010 – 2017 ($MILLION)
    TABLE 9 IODINATED-LOCM MARKET REVENUE,BY GEOGRAPHY, 2010 – 2017 ($MILLION)
    TABLE 10 IODINATED-HOCM MARKET REVENUE,BY GEOGRAPHY, 2010 – 2017 ($MILLION)
    TABLE 11 GADOLINIUM-BASED CONTRAST MEDIA MARKET REVENUE,BY GEOGRAPHY, 2010 – 2017 ($MILLION)
    TABLE 12 GLOBAL CONTRAST AGENT MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($MILLION)
    TABLE 13 ORAL CONTRAST AGENT MARKET REVENUE, BY GEOGRAPHY,2010 – 2017 ($MILLION)
    TABLE 14 INJECTABLE CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
    TABLE 15 INJECTABLE MARKET REVENUE, BY TYPE,2010 – 2017 ($MILLION)
    TABLE 16 INTRAVENOUS INJECTABLE MARKET REVENUE,BY GEOGRAPHY, 2010 – 2017 ($MILLION)
    TABLE 17 INTRA-ARTERIAL INJECTABLE MARKET REVENUE,BY GEOGRAPHY, 2010 – 2017 ($MILLION)
    TABLE 18 RECTAL CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY,2010 – 2017 ($MILLION)
    TABLE 19 URETHRAL MARKET REVENUE, BY GEOGRAPHY,2010 – 2017 ($MILLION)
    TABLE 20 MARKET REVENUE, BY MEDICAL PROCEDURE, 2010 – 2017 ($MILLION)
    TABLE 21 X-RAY – MARKET REVENUE, BY GEOGRAPHY,2010 – 2017 ($MILLION)
    TABLE 22 CT – MARKET REVENUE, BY GEOGRAPHY,2010 – 2017 ($MILLION)
    TABLE 23 MRI – MARKET REVENUE, BY GEOGRAPHY,2010 – 2017 ($MILLION)
    TABLE 24 ULTRASOUND – MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
    TABLE 25 CATH LAB MARKET REVENUE, BY GEOGRAPHY,2010 – 2017 ($MILLION)
    TABLE 26 GLOBAL MARKET, BY INDICATION,2010 – 2017 ($MILLION)
    TABLE 27 CARDIOVASCULAR DISEASES – BY GEOGRAPHY, 2010 – 2017 ($MILLION)
    TABLE 28 NEUROLOGICAL DISORDERS – BY GEOGRAPHY, 2010 – 2017 ($MILLION)
    TABLE 29 RESPIRATORY DISEASES – MARKET REVENUE,BY GEOGRAPHY, 2010 – 2017 ($MILLION)
    TABLE 30 GASTROINTESTINAL DISORDERS – MARKET,BY GEOGRAPHY, 2010 – 2017 ($MILLION)
    TABLE 31 ONCOLOGY – BY GEOGRAPHY,2010 – 2017 ($MILLION)
    TABLE 32 MUSCULOSKELETAL ANOMALIES – BY GEOGRAPHY, 2010 – 2017 ($MILLION)
    TABLE 33 NEPHROLOGICAL DISORDERS – MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
    TABLE 34 MARKET REVENUE, BY APPLICATION,2010 – 2017 ($MILLION)
    TABLE 35 RADIOLOGY CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
    TABLE 36 INTERVENTIONAL RADIOLOGY MARKET REVENUE,BY GEOGRAPHY, 2010 – 2017 ($MILLION)
    TABLE 37 INTERVENTIONAL CARDIOLOGY MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
    TABLE 38 CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY,2010 – 2017 ($MILLION)
    TABLE 39 NORTH AMERICA: CONTRAST MEDIA MARKET, BY COUNTRY,2010 – 2017 ($MILLION)
    TABLE 40 NORTH AMERICA: BY PRODUCT,2010 – 2017 ($MILLION)
    TABLE 41 NORTH AMERICA: IODINATED MARKET, BY TYPE, 2010 – 2017 ($MILLION)
    TABLE 42 NORTH AMERICA: BY APPLICATION,2010 – 2017 ($MILLION)
    TABLE 43 NORTH AMERICA: BY INDICATION,2010 – 2017 ($MILLION)
    TABLE 44 NORTH AMERICA: BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($MILLION)
    TABLE 45 NORTH AMERICA: INJECTABLE CONTRAST MEDIA MARKET,BY TYPE, 2010 – 2017 ($MILLION)
    TABLE 46 NORTH AMERICA: BY MEDICAL PROCEDURE, 2010 – 2017 ($MILLION)
    TABLE 47 EUROPE: CONTRAST MEDIA MARKET, BY COUNTRY,2010 – 2017 ($MILLION)
    TABLE 48 EUROPE: BY PRODUCT,2010 – 2017 ($MILLION)
    TABLE 49 EUROPE: IODINATED CONTRAST MEDIA MARKET, BY TYPE,2010 – 2017 ($MILLION)
    TABLE 50 EUROPE: BY APPLICATION,2010 – 2017 ($MILLION)
    TABLE 51 EUROPE: BY INDICATION,2010 – 2017 ($MILLION)
    TABLE 52 EUROPE: BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($MILLION)
    TABLE 53 EUROPE: INJECTABLE CONTRAST MEDIA MARKET, BY TYPE,2010 – 2017 ($MILLION)
    TABLE 54 EUROPE: BY MEDICAL PROCEDURE,2010 – 2017 ($MILLION)
    TABLE 55 APAC: CONTRAST MEDIA MARKET, BY COUNTRY,2010 – 2017 ($MILLION)
    TABLE 56 APAC: BY PRODUCT,2010 – 2017 ($MILLION)
    TABLE 57 APAC: IODINATED CONTRAST MEDIA MARKET, BY TYPE,2010 – 2017 ($MILLION)
    TABLE 58 APAC: BY APPLICATION,2010 – 2017 ($MILLION)
    TABLE 59 APAC: BY INDICATION,2010 – 2017 ($MILLION)
    TABLE 60 APAC: BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($MILLION)
    TABLE 61 APAC: INJECTABLE CONTRAST MEDIA MARKET, BY TYPE,2010 – 2017 ($MILLION)
    TABLE 62 APAC: BY MEDICAL PROCEDURE,2010 – 2017 ($MILLION)
    TABLE 63 ROW: REVENUE, BY REGION,2010 – 2017 ($MILLION)
    TABLE 64 ROW: MARKET REVENUE, BY PRODUCT,2010 – 2017 ($MILLION)
    TABLE 65 ROW: IODINATED CONTRAST MEDIA MARKET, BY TYPE,2010 – 2017 ($MILLION)
    TABLE 66 ROW: BY APPLICATION,2010 – 2017 ($MILLION)
    TABLE 67 ROW: BY INDICATION,2010 – 2017 ($MILLION)
    TABLE 68 ROW: BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($MILLION)
    TABLE 69 ROW: INJECTABLE CONTRAST MEDIA MARKET REVENUE, BY TYPE,2010 – 2017 ($MILLION)
    TABLE 70 ROW: REVENUE, BY MEDICAL PROCEDURE,2010 – 2017 ($MILLION)
    TABLE 71 MERGERS & ACQUISITIONS, 2010 – 2012
    TABLE 72 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES, 2010 – 2012
    TABLE 73 NEW PRODUCT LAUNCH, 2010 – 2012
    TABLE 74 EXPANSION, 2010 – 2012
    TABLE 75 APPROVALS, 2010 – 2012
    TABLE 76 OTHER DEVELOPMENTS, 2010 – 2012
    TABLE 77 AMAG PHARMACEUTICALS: TOTAL REVENUE AND R&D EXPENSES,2009 – 2011 ($MILLION)
    TABLE 78 AMAG PHARMACEUTICALS: TOTAL REVENUE, BY SEGMENT,2009 – 2011 ($MILLION)
    TABLE 79 AMAG PHARMACEUTICALS: TOTAL PRODUCT SALES, BY PRODUCT, 2009 – 2011 ($MILLION)
    TABLE 80 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)
    TABLE 81 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE,BY SEGMENT, 2009 – 2011 ($MILLION)
    TABLE 82 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE,BY GEOGRAPHY, 2009 – 2011 ($MILLION)
    TABLE 83 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE OF HEALTHCARE SEGMENT, BY DIVISION, 2009 – 2011 ($MILLION)
    TABLE 84 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE OF HEALTHCARE SEGMENT, BY GEOGRAPHY, 2009 – 2011 ($MILLION)
    TABLE 85 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE OF CONSUMER HEALTH DIVISION, BY SEGMENT, 2009 – 2011 ($MILLION)
    TABLE 86 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE OF CONSUMER HEALTH DIVISION, BY GEOGRAPHY,2009 – 2011 ($MILLION)
    TABLE 87 COVIDIEN: NET SALES AND R&D EXPENSES, 2009 – 2011 ($MILLION)
    TABLE 88 COVIDIEN: NET SALES, BY SEGMENTS, 2009 – 2011 ($MILLION)
    TABLE 89 COVIDIEN: NET SALES, BY PHARMACEUTICAL PRODUCTS,2009 – 2011 ($MILLION)
    TABLE 90 COVIDIEN: NET SALES, BY GEOGRAPHY, 2009 – 2011 ($MILLION)
    TABLE 91 DAIICHI SANKYO CO., LTD.: NET SALES AND R&D EXPENSES,2009 – 2011 ($BILLION)
    TABLE 92 DAIICHI SANKYO CO., LTD.: NET SALES, BY GEOGRAPHY,2009 – 2011 ($MILLION)
    TABLE 93 GENERAL ELECTRIC: TOTAL REVENUE AND R&D EXPENSES,2009 – 2011 ($BILLION)
    TABLE 94 GENERAL ELECTRIC: TOTAL REVENUE, BY SEGMENTS,2009 – 2011 ($BILLION)
    TABLE 95 GENERAL ELECTRIC: TOTAL REVENUE, BY GEOGRAPHY,2009 – 2011 ($BILLION)
    TABLE 96 GENOVIS AB: TOTAL REVENUE AND R&D EXPENSES,2010 – 2012 ($THOU.S.ND)
    TABLE 97 GENOVIS AB: TOTAL REVENUE, BY GEOGRAPHY,2010 – 2012 ($THOU.S.ND)
    TABLE 98 GUERBET: TOTAL REVENUE AND R&D EXPENSES,2010 – 2012 ($MILLION)
    TABLE 99 GUERBET: TOTAL REVENUE, BY PRODUCTS, 2010 – 2012 ($MILLION)
    TABLE 100 GUERBET: TOTAL REVENUE, BY GEOGRAPHY 2010 – 2012 ($MILLION)
    TABLE 101 LANTHEUS: TOTAL REVENUE AND R&D EXPENSES,2009 – 2011 ($MILLION)
    TABLE 102 LANTHEUS: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 ($MILLION)
    TABLE 103 LANTHEUS : TOTAL REVENUE, BY GEOGRAPHY,2009 – 2011 ($MILLION)
    TABLE 104 SANOCHEMIA PHARMAZEUTIKA AG: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION)
    TABLE 105 SANOCHEMIA PHARMAZEUTIKA AG: TOTAL REVENUE, BY SEGMENT, 2010 – 2011 ($MILLION)
    TABLE 106 SANOCHEMIA PHARMAZEUTIKA AG: TOTAL REVENUE,BY GEOGRAPHY, 2010 – 2012 ($MILLION)
    TABLE 107 ACCELERATOR NORDIC AB: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($THOU.S.ND)

    LIST OF FIGURES

    FIGURE 1 CONTRAST MEDIA MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
    FIGURE 2 CONTRAST MEDIA MARKET SEGMENTATION
    FIGURE 3 MARKET DYNAMICS
    FIGURE 4 MARKET SHARE ANALYSIS,BY KEY PLAYERS, 2011
    FIGURE 5 CONTRAST MEDIA MARKET SEGMENTATION, BY PRODUCT
    FIGURE 6 CHEMISTRY OF LOW OSMOLAR CONTRAST MEDIA (LOCM)
    FIGURE 7 CHEMISTRY OF HIGH-OSMOLAR CONTRAST MEDIA (HOCM)
    FIGURE 8 MARKET SEGMENTATION, BY ROUTE OF ADMINISTRATION
    FIGURE 9 MARKET SEGMENTATION, BY MEDICAL PROCEDURE
    FIGURE 10 MARKET SEGMENTATION, BY INDICATION
    FIGURE 11 MARKET SEGMENTATION, BY APPLICATION
    FIGURE 12 KEY GROWTH STRATEGIES, 2010 – 2012
    FIGURE 13 KEY PLAYERS FOCUSING ON AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES STRATEGY, 2010 – 2012
    FIGURE 14 KEY PLAYERS FOCUSING ON NEW PRODUCT LAUNCH STRATEGY,2010 – 2012